Product
Darbepoetin alfa
Aliases
Aranesp®, Darbepoetin alfa-matching placebo
Name
ARANESP
INN Name
darbepoetin alfa
FDA Approved
Yes
10 clinical trials
1 organization
13 indications
1 document
Indication
AnemiaIndication
AnaemiaIndication
CancerIndication
lung cancerIndication
Chronic Kidney Disease with AnemiaIndication
Congestive Heart FailureIndication
Cardiovascular DiseaseIndication
Ventricular DysfunctionIndication
Heart FailureIndication
Chronic Kidney DiseaseIndication
Diabetes MellitusIndication
NSCLCClinical trial
A Randomized, Repeat Dose, Open Label, Parallel Group, Multi-center Study to Evaluate the Effect of Daprodustat Compared to Darbepoetin Alfa on Forearm Blood Flow in Participants With Anemia of Chronic Kidney Disease That Are Not Dialysis DependentStatus: Terminated, Estimated PCD: 2019-05-29
Clinical trial
A Phase III, Open-label, Confirmatory Study of MT-6548 Compared to Darbepoetin Alfa in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanStatus: Completed, Estimated PCD: 2019-01-08
Clinical trial
A Phase III, Double Blind, Confirmatory Study of MT-6548 Compared to Darbepoetin Alfa in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanStatus: Completed, Estimated PCD: 2018-12-12
Clinical trial
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin AlfaStatus: Completed, Estimated PCD: 2021-04-19
Clinical trial
Phase 3b, Randomized, Open-label, Active-controlled Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)Status: Completed, Estimated PCD: 2021-11-26
Clinical trial
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney DiseaseStatus: Completed, Estimated PCD: 2017-10-19
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle ChemotherapyStatus: Terminated, Estimated PCD: 2017-06-07
Clinical trial
A Phase 3, Multi-center, Randomized, 2-arm Parallel, Double-blind, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With AnemiaStatus: Completed, Estimated PCD: 2018-03-13
Clinical trial
Trial to Reduce Cardiovascular Events With Aranesp® TherapyStatus: Completed, Estimated PCD: 2009-03-01
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and AnemiaStatus: Completed, Estimated PCD: 2012-10-11
Document
DailyMed Label: ARANESPOrganization
Amgen Inc